Ekberg Tomas, Sörensen Jens, Engström Mats, Blomquist Erik, Sundin Anders, Anniko Matti
Department of Otorhinolaryngology and Head & Neck Surgery, University Hospital (Akademiska Sjukhuset), Uppsala, Sweden.
Acta Otolaryngol. 2007 Feb;127(2):186-93. doi: 10.1080/00016480600801407.
PET plays an important role in staging, on suspicion of recurrence and for detection of occult primary tumours in the head and neck.
Since 1998 we have used positron emission tomography (PET) with (18F)fluorodeoxyglucose (FDG) to assess selected patients. This procedure has often helped in making decisions on staging and treatment.
The case records of the first 80 patients (104 PET examinations) were studied retrospectively.
A total of 39 examinations were performed for staging. PET detected all primary tumours except two (stage T1), and staging was adjusted after 13%. In all, 33 PET examinations were performed on suspicion of recurrent tumour. In 52% of these PET determined further treatments; in 21% PET had a direct impact on the surgical planning. In 18 patients with metastases from an occult primary tumour, PET detected 39% of those tumours; in 22% it was the sole modality to do so. No recurrences or second primary tumours were detected when PET was used for follow-up of clinically cured patients. Results were similar when squamous cell carcinomas (SCCs) were considered alone as compared to the complete material. The mean standardized uptake value (SUV) was higher for cases deemed tumour-positive than in negative cases.
